---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-25-000216"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T20:07:37.976952+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q2 revenue up 21% to record $10.2M; raises FY 2025 revenue guidance

## Summary
- Q2 2025 net revenue of $10.2 million, +21% YoY; Core revenue $9.3M (+19%), PST $0.9M (+42%).
- Adjusted EBITDA positive $0.3M vs ($0.4M) in prior year; net loss narrowed to $0.2M from $1.3M.
- Raises FY 2025 revenue guidance to $39.5-$40.5M (prev. $38.5-$39.5M); gross margin guidance 61%-63% reaffirmed.
- Cash balance $8.1M at Q2-end; reiterated positive operating cash flow for FY 2025.
- Adam Kalbermatten named Chief Commercial Officer; FDA 510(k) submitted for a rare disease biologic drug.

## SEC filing metadata
- accession: 0001161697-25-000216
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169725000216/0001161697-25-000216-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169725000216/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-25-000216
- JSON: https://secwatch.observer/filing/0001161697-25-000216.json
- Plain text: https://secwatch.observer/filing/0001161697-25-000216.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.